Navigation Links
Ocera Therapeutics Closes $35.5 Million Series C Financing
Date:2/20/2008

- Funds will support Phase 3 Trials for Crohn's Disease, Pouchitis and

Other Pipeline Products -

SAN DIEGO, Feb. 20 /PRNewswire/ -- Ocera Therapeutics, a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases, has announced the completion of a $35.5 million Series C financing from a syndicate of highly-regarded investors.

New investor Montagu Newhall Associates is leading the round and is joined by InterWest Partners; AgeChem Venture Fund; Cross Creek Capital, an affiliate of Wasatch Advisors; FinTech and CDIB BioScience. Previous investors, Domain Associates, Sofinnova Ventures, and Thomas, McNerney & Partners, also participated in the round. To date, Ocera has raised a total of $62 million. In conjunction with the financing, Linda Grais of InterWest Partners will take a seat on the Ocera Board of Directors representing Montagu Newhall Associates and the Series C investors.

"I am extremely pleased with the investor confidence we've seen from this oversubscribed financing round," commented Laurent Fischer, M.D., co-founder, president and CEO of Ocera Therapeutics. "We are privileged to have attracted a syndicate of renowned investors with specific expertise in the gastrointestinal market as well as international and crossover investors and we welcome Linda Grais' guidance as she joins our board of directors."

Linda Grais M.D., J.D., is a partner with InterWest Partners and brings a wide array of experience to the team. Prior to InterWest, Dr. Grais served as founder and executive vice president of SGX Pharmaceuticals and was an attorney at Wilson Sonsini Goodrich & Rosati. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She also served as a consultant to the Institute of Medicin
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
5. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
6. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
7. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
8. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
9. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
10. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
11. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... by scientists at the University of East Anglia (UEA) ... domestic or agricultural waste to generate clean electricity. , ... of the National Academy of Sciences (PNAS), the ... by which some bacteria survive by ,breathing rocks,. , ... development of new microbe-based technologies such as fuel cells, ...
(Date:12/16/2009)... 16 Martek Biosciences Corporation (Nasdaq: MATK ... quarter and fiscal year ended October 31, 2009. Revenues ... from $90.4 million in the fourth quarter of fiscal ... diluted share, for the fourth quarter of fiscal 2009, ... per diluted share, in last year,s fourth quarter. ...
(Date:12/16/2009)... Dec. 16 Cord Blood America, Inc. ... stem cell preservation company ( http://www.cordblood-america.com ) ... stem cells, a biological insurance policy, to families ... reduced its debt by a total of $1.4 ... 2009 and total debt eliminated for the year ...
(Date:12/16/2009)... Dec. 16 Sequenom, Inc. (Nasdaq: ... Kenneth Buechler and Mr. David Pendarvis to its ... http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) ,, Kenneth F. Buechler, Ph.D., was ... Incorporated. From 1988 to 1994, Dr. Buechler was ... Dr. Buechler was a senior research scientist for ...
Breaking Biology Technology:'Rock-breathing' bacteria could generate electricity and clean up oil spills 2Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
... - When Cytochroma , a Canadian firm seeking ... Proventiv Therapeutics last year, executives indicated that the combined ... venture capital from Canadian and American investors. , ,This ... funds. , ,The company, which says it plans to ...
... - Wisconsin companies raised more venture capital in more deals ... categories, according to report from Ernst & Young, LLP ... Wisconsin reported 12 venture deals in 2006, including a $12 ... maker of genomic research tools, for a total of $58.47 ...
... - With its first accelerator building fully committed, ... spring on a new, 50,000 square foot Accelerator 2 facility. ... Wave Technologies, will help firms that are ready to "graduate" ... start-up technology companies. Suites will range in size from 2,500 ...
Other Biology Technology:Biotech with Madison ties raises $21M in capital 2Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Research park to add accelerator suites 2
(Date:12/17/2009)... A licensing agreement between the U.S. Department of ... glass provider Mo-Sci Corporation will make SRNL,s unique ... in targeted drug delivery, hydrogen storage and other ... glass microspheres have been used for years in ... What makes SRNL,s patent-pending microspheres unique is ...
(Date:12/17/2009)... genetic variant may be associated with better preserved lung ... according to a new study funded by the National ... of the National Institutes of Health. The study ... a lowered risk of developing chronic obstructive pulmonary disease ... lung disease most common among smokers, which makes it ...
(Date:12/16/2009)... ARMONK, N.Y. and FOOTHILL RANCH, Calif., Dec. ... ) and Fujitsu Frontech North America Inc. ... integrates palm vein biometric technology from Fujitsu ... ,, (Photo: http://www.newscom.com/cgi-bin/prnh/20091217/NY27736 ) ... The new offering aims to help companies ...
Breaking Biology News(10 mins):MO-SCI Corporation to manufacture, market SRNL's unique glass microspheres 2Media availability: Genetic variant may control lung function and risk of COPD 2Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 2Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 3Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 4Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 5EMBO pioneers pension plan for internationally mobile postdoctoral researchers 9517 1EMBO pioneers pension plan for internationally mobile postdoctoral researchers 9517 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 9517 3Navigating in the ocean of molecules 9514 1Navigating in the ocean of molecules 9514 2Navigating in the ocean of molecules 9514 3Photo 3A New Survey Results Show Most Moms Are Aware Their Pre teens and Teens Need Vaccines 53947 1Photo 3A New Survey Results Show Most Moms Are Aware Their Pre teens and Teens Need Vaccines 53947 2Photo 3A New Survey Results Show Most Moms Are Aware Their Pre teens and Teens Need Vaccines 53947 3
... in the U.S. and abroad is likely to change ... short-term goals to reduce carbon emissions, according to a ... of the Institute for Operations Research and the Management ... Methods: An Application to Global Climate Change Policy" is ...
... word evokes memories of promising spring days and visions of ... America,s yards and gardens, and have played a storied role ... Europe, lilacs were brought to North America by the first ... 1800. The oldest living lilacs in North America may be ...
... carbon footprint, recycling more, and going green be ... impact? That,s the question a team of Canadian ... their findings in a forthcoming issue of the ... from Inderscience Publishers. , The researchers recruited ...
Other Biology News:Don't count on long-term success in climate policy, warns paper in Decision Analysis 2Patriotic new lilacs introduced 2Shrinking carbon footprints 2Shrinking carbon footprints 3